Latest Evido Health News & Updates

Evido publishes research letter on LiverPRO

It shows 71% fewer unnecessary referrals and 29% lower cost per detected case versus FIB-4 for liver fibrosis detection in SLD patients.

Evido highlights LiverPRO outperforming FIB-4

Studies at EASL SLDSummit2026 show LiverPRO improves fibrosis risk stratification, identifying more cases and reducing misses.

Evido highlights LiverPRO in EASL guidance

LiverPRO is recommended as a scalable first-line non-invasive test for liver fibrosis in steatotic liver disease using routine blood data.

Evido highlights LiverPRO in EASL abstracts

Abstracts confirm LiverPRO outperforms FIB-4 in detecting early liver fibrosis. Multiple studies validate its superior performance in risk stratification and validation.

Former Coloplast CEO becomes chair and co-owner of Danish health tech-startup

After leaving Coloplast in May, Villumsen has embarked on a career as a board member and investor.

Danish healthtech company Evido Health partners with Roche

Evido Health gains muscle partnering with Roche to more effectively sell its software solution for early detection of chronic liver disease,...

Medtech: A company portrait of Evido Health

The company has developed software that uses artificial intelligence (AI) to detect liver diseases based on so-called biomarkers in patient blood samples.

Video Game Survey Shows Potential for Healthcare Applications